Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPI-818 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| CPI-818 Dose Escalation | EXPERIMENTAL | Participants will receive CPI-818 capsule, orally, twice per day at an assigned dose, till disease progression, complete response or remission (CR) for \>2 months or if dose determined to be unsafe. |
| CPI-818 Dose Expansion phase | EXPERIMENTAL | Participants with different T-cell lymphoma sub-types will receive CPI-818 capsules at the specific dose selected from the Dose escalation phase of the study. CPI-818 capsules at the selected dose will be taken orally, twice per day until disease progression or CR for \> 2 months. |
| Name | Type | Description |
|---|---|---|
| CPI-818 | DRUG | Interleukin-2 inducible T-cell Kinase Inhibitor |
Inclusion Criteria: * Adult subjects age ≥18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Histologically confirmed evidence of T-cell lymphoma * Measurable disease. * Adequate organ function. * At least 2 standard therapies for advanced or recurrent disease or ha...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
CPI-818 is an investigational small molecule being developed for the treatment of T-cell lymphoma. It is currently in Phase 1 clinical development for this indication.
CPI-818 targets ITK, an enzyme involved in T-cell signaling. By inhibiting ITK, CPI-818 is designed to interfere with pathways relevant to T-cell lymphoma.
CPI-818 is being developed by Corvus Pharmaceuticals, Inc., a biopharmaceutical company. The company is listed on the NASDAQ under the ticker symbol CRVS.
CPI-818 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities.
CPI-818 is being studied in a Phase 1 dose escalation trial (NCT03952078) for relapsed or refractory T-cell lymphoma. The trial is active but not recruiting, with an enrollment of 151 participants across the United States, Australia, China, and South Korea.
CPI-818 is the primary name for this investigational compound. No alternative names have been reported for CPI-818 in its clinical development.